An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used in the proposed dosages for previously treated adult patients with ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Oncologic Drugs Advisory Committee (ODAC) has voted against the benefit/risk profile of GSK’s Blenrep (belantamab mafodotin) just days before the drug’s Prescription Drug User Fee Act (PDUFA) date.

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...

Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.

GSK plc GSK announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted against the overall benefit/risk profile of the Blenrep (belantamab mafodotin-blmf) combination therapy at the ...

The consumer-goods company is selling a majority stake in its home-care business to Advent International as it looks to sharpen its focus on core brands. The company reported a second-quarter earnings ...

The agreement, signed Monday between CMS and DHS, has not been announced publicly, AP reports. Other Trump administration news is on gender-affirming care for youth, President Donald Trump's vein ...

The agreement, signed Monday between CMS and DHS, has not been announced publicly, AP reports. Other Trump administration ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

London’s FTSE 100 was up 0.2% at 8,986.82 in afternoon trade on Friday. BP was in the black as the oil giant agreed to sell ...